Loading...

Fusion Antibodies

AIM:FAB
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FAB
AIM
£14M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Fusion Antibodies has significant price volatility in the past 3 months.
FAB Share Price and Events
7 Day Returns
0%
AIM:FAB
3.2%
GB Life Sciences
-0.2%
GB Market
1 Year Returns
-48.8%
AIM:FAB
5.2%
GB Life Sciences
-1.4%
GB Market
FAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fusion Antibodies (FAB) 0% 15.3% 113.3% -48.8% - -
GB Life Sciences 3.2% -0.2% 10.8% 5.2% 27.8% 50.2%
GB Market -0.2% 1.7% 0.2% -1.4% 11.7% 7.5%
1 Year Return vs Industry and Market
  • FAB underperformed the Life Sciences industry which returned 5.2% over the past year.
  • FAB underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -1.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

FAB Value

 Is Fusion Antibodies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fusion Antibodies. This is due to cash flow or dividend data being unavailable. The share price is £0.64.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fusion Antibodies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fusion Antibodies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:FAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in GBP £-0.06
AIM:FAB Share Price ** AIM (2019-07-16) in GBP £0.64
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 40.25x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 790 Publicly-Listed Companies 16.56x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fusion Antibodies.

AIM:FAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:FAB Share Price ÷ EPS (both in GBP)

= 0.64 ÷ -0.06

-11.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fusion Antibodies is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • Fusion Antibodies is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Fusion Antibodies's expected growth come at a high price?
Raw Data
AIM:FAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.92x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 573 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fusion Antibodies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fusion Antibodies's assets?
Raw Data
AIM:FAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in GBP £0.24
AIM:FAB Share Price * AIM (2019-07-16) in GBP £0.64
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 2.23x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,377 Publicly-Listed Companies 1.5x
AIM:FAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:FAB Share Price ÷ Book Value per Share (both in GBP)

= 0.64 ÷ 0.24

2.64x

* Primary Listing of Fusion Antibodies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fusion Antibodies is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Fusion Antibodies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Fusion Antibodies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FAB Future Performance

 How is Fusion Antibodies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fusion Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.5%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fusion Antibodies expected to grow at an attractive rate?
  • Unable to compare Fusion Antibodies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Fusion Antibodies's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Fusion Antibodies's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AIM:FAB Future Growth Rates Data Sources
Data Point Source Value (per year)
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 23.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -3.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:FAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:FAB Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-03-31 2 -1 -1
2018-09-30 2 0 -1
2018-06-30 2 0 -1
2018-03-31 3 0 -1
2017-03-31 2 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Fusion Antibodies is high growth as no earnings estimate data is available.
  • Unable to determine if Fusion Antibodies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:FAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Fusion Antibodies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:FAB Past Financials Data
Date (Data in GBP Millions) EPS *
2019-03-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.04
2017-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fusion Antibodies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of FAB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Fusion Antibodies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Fusion Antibodies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Fusion Antibodies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fusion Antibodies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FAB Past Performance

  How has Fusion Antibodies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fusion Antibodies's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fusion Antibodies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fusion Antibodies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fusion Antibodies's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Fusion Antibodies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fusion Antibodies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:FAB Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2.18 -1.26 1.97
2018-09-30 1.94 -1.28 0.79
2018-06-30 2.31 -0.99 1.18
2018-03-31 2.69 -0.70 1.57
2017-03-31 1.91 0.12 0.85
2016-03-31 1.48 1.15 0.84
2014-03-31 0.72 -0.11 0.35 0.16
2013-03-31 0.40 -0.47 0.36 0.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fusion Antibodies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fusion Antibodies has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fusion Antibodies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fusion Antibodies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fusion Antibodies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FAB Health

 How is Fusion Antibodies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fusion Antibodies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fusion Antibodies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fusion Antibodies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fusion Antibodies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 23.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fusion Antibodies Company Filings, last reported 3 months ago.

AIM:FAB Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 5.35 0.00 1.98
2018-09-30 5.84 0.00 2.80
2018-06-30 5.84 0.00 2.80
2018-03-31 6.58 0.00 4.49
2017-03-31 1.71 0.00 0.29
2016-03-31 1.46 0.00 0.41
2014-03-31 0.00 0.00 0.14
2013-03-31 0.03 0.00 0.13
  • Fusion Antibodies's level of debt (2.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 2.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fusion Antibodies has less than a year of cash runway based on current free cash flow.
  • Fusion Antibodies has less than a year of cash runway if free cash flow continues to grow at historical rates of 84.4% each year.
X
Financial health checks
We assess Fusion Antibodies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fusion Antibodies has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FAB Dividends

 What is Fusion Antibodies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fusion Antibodies dividends.
If you bought £2,000 of Fusion Antibodies shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fusion Antibodies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fusion Antibodies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:FAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.2%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 1.9%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fusion Antibodies has not reported any payouts.
  • Unable to verify if Fusion Antibodies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fusion Antibodies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fusion Antibodies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Fusion Antibodies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fusion Antibodies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fusion Antibodies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FAB Management

 What is the CEO of Fusion Antibodies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Kerr
COMPENSATION £91,939
AGE 47
TENURE AS CEO 7.8 years
CEO Bio

Dr. Paul Gerard Kerr, Ph.D. has been Chief Executive Officer of Fusion Antibodies plc (also known as Fusion Antibodies Ltd.) since September 2011 and has been its Director since 2011. Dr. Kerr has been with Fusion Antibodies Ltd with over 10 years in a variety of technical roles, then 8 years in Business Development charged with developing the Contract Research services and seeking partners for the drug assets. Dr. Kerr has more than 20 years of Experience in Bioscience. He also serves as a Director of Fusion Antibodies Ltd.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Fusion Antibodies management team in years:

7.8
Average Tenure
47
Average Age
  • The average tenure for the Fusion Antibodies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Paul Kerr

TITLE
CEO & Director
COMPENSATION
£92K
AGE
47
TENURE
7.8 yrs

James Fair

TITLE
CFO, Company Secretary & Director
COMPENSATION
£91K
AGE
53
TENURE
1.9 yrs

Richard Buick

TITLE
CTO & Director
COMPENSATION
£92K
AGE
42
TENURE
7.8 yrs

Jim Johnston

TITLE
Board of Directors Tenure

Average tenure and age of the Fusion Antibodies board of directors in years:

7.8
Average Tenure
56.5
Average Age
  • The tenure for the Fusion Antibodies board of directors is about average.
Board of Directors

Simon Douglas

TITLE
Non-Executive Chairman
COMPENSATION
£23K
AGE
60
TENURE
7.8 yrs

Paul Kerr

TITLE
CEO & Director
COMPENSATION
£92K
AGE
47
TENURE
8.5 yrs

James Fair

TITLE
CFO, Company Secretary & Director
COMPENSATION
£91K
AGE
53
TENURE
1.9 yrs

Richard Buick

TITLE
CTO & Director
COMPENSATION
£92K
AGE
42
TENURE
7.8 yrs

Colin Walsh

TITLE
Non-Executive Director
COMPENSATION
£8K
AGE
63
TENURE
12.5 yrs

Tim Watts

TITLE
Non-Executive Director
COMPENSATION
£8K
AGE
61
TENURE
1.6 yrs

Sonya Ferguson

TITLE
Senior Independent Director
COMPENSATION
£7K
AGE
48

Alan Mawson

TITLE
Non-Executive Director
COMPENSATION
£7K
AGE
77
TENURE
15.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Fusion Antibodies individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
03. Jul 19 Buy Paul Kerr Individual 02. Jul 19 02. Jul 19 6,920 £0.73 £5,044
03. Jul 19 Buy Alan Mawson Individual 02. Jul 19 02. Jul 19 10,000 £0.59 £5,900
29. Apr 19 Buy Paul Kerr Individual 29. Apr 19 29. Apr 19 1,290 £0.77 £993
03. Dec 18 Buy Alan Mawson Individual 30. Nov 18 30. Nov 18 5,000 £0.53 £2,625
25. Sep 18 Buy Richard Buick Individual 25. Sep 18 25. Sep 18 3,000 £0.70 £2,113
25. Sep 18 Buy Alan Mawson Individual 24. Sep 18 24. Sep 18 8,500 £0.67 £5,695
X
Management checks
We assess Fusion Antibodies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fusion Antibodies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FAB News

Simply Wall St News

What Type Of Shareholder Owns Fusion Antibodies plc's (LON:FAB)?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Fusion Antibodies is not a large company by global standards. … See our latest analysis for Fusion Antibodies AIM:FAB Ownership Summary, June 19th 2019 What Does The Institutional Ownership Tell Us About Fusion Antibodies? … We can see that Fusion Antibodies does have institutional investors; and they hold 33% of the stock.

Simply Wall St -

Did You Manage To Avoid Fusion Antibodies's (LON:FAB) Painful 51% Share Price Drop?

Fusion Antibodies isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … In just one year Fusion Antibodies saw its revenue fall by 16%.

Simply Wall St -

What Investors Should Know About Fusion Antibodies Plc's (LON:FAB) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is FAB right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Was Fusion Antibodies Plc's (LON:FAB) Earnings Decline Part Of A Broader Industry Downturn?

After looking at Fusion Antibodies Plc's (AIM:FAB) latest earnings update (31 March 2017), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … See our latest analysis for Fusion Antibodies How Well Did FAB Perform? … For Fusion Antibodies, its latest earnings (trailing twelve month) is UK£119.95K, which, in comparison to last year’s level, has plunged by a large -89.61%.

Simply Wall St -

Fusion Antibodies Plc (LON:FAB): Can It Deliver A Superior ROE To The Industry?

View our latest analysis for Fusion Antibodies What you must know about ROE Return on Equity (ROE) weighs Fusion Antibodies’s profit against the level of its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Fusion Antibodies’s equity capital deployed. … Given a discrepancy of -1.27% between return and cost, this indicated that Fusion Antibodies may be paying more for its capital than what it’s generating in return.

Simply Wall St -

FAB Company Info

Description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody identification and discovery services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies worldwide. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Details
Name: Fusion Antibodies plc
FAB
Exchange: AIM
Founded: 2000
£14,138,362
22,091,192
Website: http://www.fusionantibodies.com
Address: Fusion Antibodies plc
1 Springbank Road,
Springbank Industrial Estate,
Belfast,
County Antrim, BT17 0QL,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM FAB Ordinary Shares London Stock Exchange AIM Market GB GBP 18. Dec 2017
Number of employees
Current staff
Staff numbers
33
Fusion Antibodies employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 22:12
End of day share price update: 2019/07/16 00:00
Last earnings filing: 2019/07/02
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.